The 2026 IPO window blew open this summer. SpaceX's June listing pulled in a reported $86 billion according to Benzinga and other outlets, and Anthropic is now being floated as the next challenger to that record, with OpenAI chatter never far behind.
IP Group PLC (LSE:IPO) has seen a bullish write-up from European investment bank Berenberg, which pitches a 'Buy' rating and a 119p price target that implies around 70% upside to its current price. Berenberg describes IP Group, the investor in early-stage companies, as an “underappreciated asset” whilst noting the current 40% discount to NAV despite improving portfolio valuations and a strong liquidity position.
The board of IP Group PLC (LSE:IPO), the London-listed technology investor, may struggle to recommend an improved takeover proposal from pension fund Railpen without further concessions, according to Deutsche Bank. Railpen returned with a revised offer ahead of today's put up or shut up deadline, when it must either make a firm bid or walk away.
Railpen has raised its takeover proposal for IP Group PLC (LSE:IPO), offering shareholders a mix of cash, shares in Oxford Nanopore and a contingent payout linked to the biotech firm Metsera. The pension fund manager, IP Group's largest shareholder with an 18.4% stake, has made two improved proposals to the board since its initial approach on 22 June, following meetings with shareholders and directors.
IP Group PLC (LSE:IPO), the company that backs spin-out businesses, has rejected a takeover proposal from one of its largest shareholders, the railways pension scheme Railpen. The board said the proposal, received on 16 June, materially undervalued the company and its prospects, and was turned down unanimously.
Deutsche Bank has said it is 'unsurprised' that IP Group PLC (LSE:IPO) rejected a take-private approach from Railpen, its largest shareholder. The bank, whose analyst Kane Slutzkin rates the stock a 'buy' with a 110p price target, said the non-binding proposal undervalued the company on several counts.
IP Group PLC (LSE:IPO), the London-listed investor that backs science and technology start-ups, has rejected a £616 million takeover approach from its largest shareholder. The approach came from Railpen, which manages the Railways Pension Scheme and holds 18.4% of IP Group.
IP Group PLC (LSE:IPO), the FTSE 250 investment company focused on science and technology businesses, has announced that portfolio company Istesso has begun dosing patients in a phase II trial of its lead drug candidate. The study, named IST-03, is testing leramistat in patients with sarcopenia, a condition involving muscle loss, caused by rheumatoid arthritis.
IP Group PLC (LSE:IPO), the LSE-listed science and technology investor, has appointed Michael Queen as non-executive director and chair designate, concluding a succession process announced last year. Queen will take over as chair following the company's annual general meeting on 18 June 2026, when Sir Douglas Flint retires from the board after nearly eight years of service.
First Light Fusion, an IP Group PLC (LSE:IPO) portfolio company developing inertial fusion energy technology, has raised £25 million in the first close of a new funding round led by specialist fusion fund Starmaker One and backed by the UK Atomic Energy Authority (UKAEA). The round was led by East X Ventures, a UK venture firm, through its Starmaker One fusion fund, with a significant strategic investment from the UKAEA, the government body responsible for leading the UK's fusion energy programme.
IP Group PLC (LSE:IPO), the LSE-listed science and technology investor, has launched a new fund with Australia's Clean Energy Finance Corporation (CEFC) to back cleantech companies targeting hard-to-abate industries. The IP Group Climate Catalyst Fund has a target size of up to A$150 million, with IP Group contributing A$30 million and the CEFC A$20 million as cornerstone investors at first close.
Analysts at three brokerages maintain 'buy' ratings after strong full-year results IP Group PLC (LSE:IPO), the London-listed investor that commercialises intellectual property from leading universities, reported a 13% rise in net asset value (NAV) per share to 110.4p for the year ended December 2025, driven by a licensing deal tied to Pfizer's $10 billion acquisition of obesity drug developer Metsera. The company's shares rose 11% on Tuesday to 54.7p.